Benzinga | Jul 15, 2021 08:53AM EDT

Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy

* Advaxis Inc (NASDAQ:ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.

* The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.

* The Phase 1 open-label dose-escalation study will evaluate the safety and tolerability of two dose levels of ADXS-504 monotherapy.

* The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.

* Recently, the Company has announced a reverse merger agreement with privately-held Biosight Ltd.

* Price Action: ADXS shares are up 3.7% at $0.45 during the premarket session on the last check Thursday.